(redirected from Advanced Renal Cell Carcinoma)
Category filter:
ARCCAdvanced Renal Cell Carcinoma (cancer)
ARCCAssociation for the Rights of Catholics in the Church
ARCCAnoka Ramsey Community College
ARCCAlliance for Research in Chicagoland Communities (Chicago, IL)
ARCCArchitectural Research Centers Consortium
ARCCAfrican Regional Centre for Computing
ARCCAeronautical Rescue Coordination Centre (Swedish)
ARCCAIM Research Conference Center
ARCCAutorité de Régulation du Café et du Cacao (French)
ARCCAlum Rock Counseling Center
ARCCAssociation of Rootes Car Clubs
ARCCArea Repeater Coordination Council
ARCCAmerican Rivers Conservation Council
ARCCAssociation Réunionnaise Communication et Culture
ARCCAdirondack Regional Chamber of Commerce
ARCCArecibo Remote Command Center (University of Texas at Brownsville)
ARCCArchives and Research Collections Centre
ARCCAcquisition Reform Communications Center
ARCCAssociation of Regional Chambers of Commerce
ARCCAdvancing Research and Clinical practice through Close Collaboration
ARCCAmerican Red Cross Club
ARCCAssociation Régionale de Camping et de Caravaning (Montreal, Canada)
ARCCAfrican Regional Center for Computing
ARCCAssociation of Reconciling Christians and Congregations
ARCCArrowhead Regional Computing Consortium
ARCCArtificial Retina Component Chip
ARCCAssociation of Regional Conservation Centers
ARCCAthletic, Recreation, and Community Center
ARCCAwareness of Roots in Chinese Culture
ARCCAfrican Regional Certification Commission
ARCCAberdeen Recreation and Cultural Center
ARCCAllied Riser Communications Corporation
ARCCAcademic Resources and Computing Committee
ARCCAlbuquerque Rape Crisis Center (New Mexico)
ARCCAccounts Receivable Core Committee
ARCCAvian Records Committee of Connecticut
ARCCArmy Reserve Career Counselor (US Army)
ARCCAt-Risk Child Care
ARCCAlfa Romeo Club of Canada
ARCCAthletic Recreation Convocation Complex
ARCCAlexandria Republican City Committee
ARCCAviation Rulemaking Cost Committee (FAA)
ARCCActualisation Resource Counselling & Certification (UK)
ARCCAeronautical Rescue Coordination Center
ARCCAge-Related Cortical Cataract
ARCCAnimal Research and Care Committee
ARCCAlzheimer Research Center of California
ARCCAnimal Related Communications Consultants
ARCCAmateur Radio Caravan and Camping Club
ARCCAluminum Reinforced Carbon Composite
ARCCAir Rescue Coordination Center
ARCCAction Research for the Crippled Child
ARCCAdvanced Resin Coated Copper (MEW Japan)
ARCCAmateur Radio Caravan Club
ARCCAshanti Regional Co-ordinating Council
ARCCAlliance for Responsible Use of Chlorine Chemistry
ARCCAbbeyville Road Christian Church
ARCCalt.religion.christian.calvary-chapel (newsgroup)
ARCCAddison Road Community Centre
ARCCAdventures Cross-Country, Inc.
ARCCAdventures Cross Country, Inc.
ARCCArchbishop Ryan Computer Club
ARCCArmy Requirements Coordinating Committee
ARCCAston Rowant Cricket Club
ARCCArchitectural Control Committee
ARCCAnaheim Religious Community Council (California)
ARCCAllergy and Respiratory Clinic for Children
ARCCAustralian Research Consultative Committee
ARCCAgape Revival Christian Church
ARCCApplied Recycling Competence Center
ARCCAmerica Reads & Counts Challenge
ARCCAllied Command Europe Rapid Reaction Corps
ARCCAllakhazam Magical Realm
ARCCAirborne Reproductive Choice Campaign
ARCCAccounts Receivable and Claims Control
ARCCASEAN Regional Call Center
ARCCAssociazione Regionale delle Cooperative di Consumatori
ARCCAssociation pour la Recherche en Conjuration/Convocation
ARCCAlumnae Resource Career Connection
ARCCApplication for Removal to Circuit Court
ARCCAfrica Regional Coordinating Committee for the Integration of Women Into Development
ARCCAiguille Rock Climbing Center, Inc.
ARCCArthritis Research Centre of Canada
ARCCAgricultural Research Centre of Crete and Islands
ARCCAverage Runlength-Constrained Code
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
ENPNewswire-July 30, 2019--European Medicines Agency Adopts Positive Opinion for Merck's KEYTRUDA in Combination with Inlyta as First-Line Treatment for Advanced Renal Cell Carcinoma
Calithera Biosciences (CALA), up 8% after announcing results from its randomized placebo-controlled Phase 2 ENTRATA study of telaglenastat in combination with everolimus in patients with advanced renal cell carcinoma...
United States-based Exelixis Incorporated announced yesterday that it is starting COSMIC-313, a phase three pivotal trial of cabozantinib (CABOMETYX) in combination with nivolumab (Opdivo) and ipilimumab (Yervoy) versus nivolumab and ipilimumab in patients with earlier untreated advanced renal cell carcinoma (RCC) with intermediate- or poor-risk disease per the International Metastatic Renal Cell Carcinoma Database Consortium.
The clinical trial involved 886 patients with previously untreated, advanced renal cell carcinoma who were randomised to receive the drug combination or sunitinib alone.
EMD Serono stated on Monday that its supplemental Biologics License Application (sBLA) for BAVENCIO (avelumab) in combination with INLYTA (axitinib) has passed US Food and Drug Administration (FDA) priority review in patients with advanced renal cell carcinoma (RCC), the most common form of kidney cancer.
- Updated results show antitumor activity with a consistent safety profile in advanced renal cell carcinoma (RCC) and advanced endometrial carcinoma (EC)
Laparoscopic management of advanced renal cell carcinoma with renal vein and inferior vena cava thrombus.
The investigators started their phase-1 clinical trial of this combination in 2014 and enrolled 52 advanced renal cell carcinoma (the most common form of kidney cancer) patients who had not previously been treated for the disease.
Nivolumab, marketed as Opdivo, is a human monoclonal antibody used in the treatment of advanced renal cell carcinoma. Common side effects include cough, nausea, asthenic conditions, rash, and dyspnea.
Leibovich, "Management of inferior vena cava tumor thrombus in locally advanced renal cell carcinoma," Therapeutic Advances in Urology, vol.
(NYSE: PFE) today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for avelumab in combination with INLYTAA(r) (axitinib) for treatment-naive patients with advanced renal cell carcinoma (RCC).
Sexton, "Management of locally advanced renal cell carcinoma," Cancer Control, vol.
Full browser ?